Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 1 February 2006, Vol. 107, No. 3, pp. 851.

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Plow, E. F.
Right arrow Articles by Pluskota, E.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Plow, E. F.
Right arrow Articles by Pluskota, E.
Related Collections
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow


InsideBlood

HEMOSTASIS

Comment on Li et al, page 965

MAPkinaseQuest: novel roadway to {alpha}IIbbeta3 activation

Edward F. Plow, and Elzbieta Pluskota

CLEVELAND CLINIC FOUNDATION

In this issue, Li and colleagues delineate a novel signaling pathway, in which 2 MAPK kinases are shown to regulate the activation of integrin {alpha}IIbbeta3 on platelets.

Platelet stimulation begins with the binding of agonists, such as thrombin and von Willebrand factor (VWF) to receptors on the plasma membrane. These interactions transduce a series of intracellular signaling events, collectively referred to as inside-out signaling, which culminate in the conversion of the major platelet integrin, {alpha}IIbbeta3, from a quiescent state to an active conformer form capable of binding the soluble ligands. Such activation of {alpha}IIbbeta3 is essential for platelet aggregation, an event of critical importance not only in the maintenance of hemostasis but also to the development of myocardial infarction, stroke, and other thrombotic diseases. Thus, the pathways of inside-out signaling and {alpha}IIbbeta3 activation have been intensively investigated (reviewed in Shattil and Newman1).

Li and colleagues identify a previously unappreciated inside-out signaling pathway. Using pharmacologic and molecular biologic approaches, p38 MAPK is implicated in agonist-stimulated platelet activation. First, 2 inhibitors of p38 MAPK, SB203580 and SB202190, are shown to abrogate platelet aggregation triggered either by VWF interacting with GPIb-IX or by low-dose thrombin or thrombin receptor activating peptides (TRAPs) interacting with PAR1 and PAR 4. Hence, p38 MAPK is involved in platelet activation mediated by 2 major physiologic agonists. Second, VWF-GPIb-IX-mediated activation of {alpha}IIbbeta3 in Chinese Hamster Ovary (CHO) cells expressing the platelet receptors is markedly inhibited by cotransfection with a dominant-negative mutant of p38 MAPK. This effect, detected as a significant attenuation of fibrinogen binding to {alpha}IIbbeta3,is not due to reduced expression of the integrin or GPIb-IX. If blockade of p38 MAPK activity reduces activation of {alpha}IIbbeta3, then VWF and thrombin might trigger phosphorylation of p38 MAPK in platelets. Indeed, the investigators found that both VWF and thrombin stimulated rapid and transient phosphorylation not only of p38 MAPK but also of another MAPK family member, ERK2. Although p38 MAPK and ERK2 are regarded as parallel pathways in many biologic systems,2 the authors show that p38 MAPK is upstream of ERK2 activation, as p38 MAPK inhibitors and the dominant-negative mutant of p38 MAPK diminished phosphorylation of ERK2. The authors previously reported that engagement of GPIb-IX and PARs increases intracellular cGMP, leading to activation of cGMP-dependent protein kinase (PKG), which, in turn, induces activation of {alpha}IIbbeta3 via phosphorylation of ERK2. In the present study, these investigators demonstrate that PKG activation is upstream of VWF- and thrombin-triggered p38 MAPK phosphorylation; this event is completely blocked by specific inhibitors of PKG and is not observed in PKG-knockout mice. Taken together, Li et al have characterized a novel inside-out signaling pathway (see figure) in which physiologic platelet agonists sequentially induce activation of PKG, p38 MAPK, and ERK2, leading to {alpha}IIbbeta3 activation. Remaining to be elucidated are the upstream, how agonists trigger PKG activation, and downstream, how ERK2 regulates {alpha}IIbbeta3 activation events. Nevertheless, the present study redraws the inside-out signaling map, placing p38 MAPK as a critical mediator of platelet activationandexpandinginterestinitasatargetfor protection against cardiovascular diseases.3 {blacksquare}


Figure 1
View larger version (50K):
[in this window]
[in a new window]
 
Novel signaling pathway leading to {alpha}IIbbeta3 activation. Interaction of VWF or thrombin with their receptors on platelet membrane results in an increase of intracellular cGMP levels, leading to activation of cGMP-dependent protein kinase (PKG). This kinase is upstream of p38 MAPK and ERK2 phosphorylation, which is crucial in {alpha}IIbbeta3 activation.

 
References

  1. Shattil SJ, Newman PJ. Integrins: dynamic scaffolds for adhesion and signaling in platelets. Blood. 2004;104: 1606-1615.[Abstract/Free Full Text]

  2. Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev. 2001;81: 807-869.[Abstract/Free Full Text]

  3. Gao F, Yue TL, Shi DW, et al. p38 MAPK inhibition reduces myocardial reperfusion injury via inhibition of endothelial adhesion molecule expression and blockade of PMN accumulation. Cardiovasc Res. 2002;53: 414-422.[Abstract/Free Full Text]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article in Blood Online:

Sequential activation of p38 and ERK pathways by cGMP-dependent protein kinase leading to activation of the platelet integrin {alpha}IIbbeta3
Zhenyu Li, Guoying Zhang, Robert Feil, Jiahuai Han, and Xiaoping Du
Blood 2006 107: 965-972. [Abstract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
BloodHome page
A. J. Begonja, J. Geiger, N. Rukoyatkina, S. Rauchfuss, S. Gambaryan, and U. Walter
Thrombin stimulation of p38 MAP kinase in human platelets is mediated by ADP and thromboxane A2 and inhibited by cGMP/cGMP-dependent protein kinase
Blood, January 15, 2007; 109(2): 616 - 618.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Plow, E. F.
Right arrow Articles by Pluskota, E.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Plow, E. F.
Right arrow Articles by Pluskota, E.
Related Collections
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
Sponsor: Genentech BioOncology and and Biogen Idec
Blood Online is supported in part by
Genentech BioOncology and Biogen Idec
  Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020